Kovid-19: Britain approves this new therapy for people with weak immune response

The Medicines and Healthcare products Regulatory Agency (MHRA) said on Thursday that the government’s independent scientific advisory body supported the decision to approve the treatment after reviewing the evidence. A new drug, Evushield (tixagevimab/cilgavimab), has been approved for prevention of covid-19 By Medicines and Healthcare products Regulatory Agency (MHRA) after meeting UK regulatory standards of safety, quality and effectiveness, according to a government release.

The World Health Organization said this week that this could be a huge problem amid data showing a global increase in Covid-19 cases, warning nations this week to be cautious as some countries also report declining testing rates. We do.

The MHRA said Anglo-Swedish drug maker AstraZeneca’s antibody cocktail, branded Evusheld, was found to reduce the risk of developing symptomatic COVID-19 by 77% in the trial, with a single dose following as low as 77%. Security was there for at least six months. It is authorized in the United States to prevent COVID-19 infection in individuals with already weakened immune systems or a history of serious side effects from coronavirus vaccines.

The UK has given a similar approval and the MHRA has stated that the treatment, given as an intra-muscular injection, should not be administered to people infected with the SARS-CoV-2 virus caused by COVID or Those who have recently come in contact with someone. virus, according to Reuters report good.

Additionally, the regulator cautioned that there was insufficient data to fully evaluate EvuShield’s effectiveness against the Omicron variant or how long it would work against the variant, saying it would be contacting AstraZeneca on that. Used to be. In December AstraZeneca said a laboratory study found that the antibody cocktail produced neutralizing activity against Omicron, reporting the first such data for the treatment.

(with inputs from agencies)